0001209191-23-048453.txt : 20230906
0001209191-23-048453.hdr.sgml : 20230906
20230906172554
ACCESSION NUMBER: 0001209191-23-048453
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230901
FILED AS OF DATE: 20230906
DATE AS OF CHANGE: 20230906
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DeFord John A
CENTRAL INDEX KEY: 0001403373
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35621
FILM NUMBER: 231240221
MAIL ADDRESS:
STREET 1: C R BARD INC
STREET 2: 730 CENTRAL AVENUE
CITY: MURRAY HILL
STATE: NJ
ZIP: 07974
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GLOBUS MEDICAL INC
CENTRAL INDEX KEY: 0001237831
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 043744954
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2560 GENERAL ARMISTEAD AVENUE
CITY: AUDUBON
STATE: PA
ZIP: 19403
BUSINESS PHONE: 610-930-1800
MAIL ADDRESS:
STREET 1: 2560 GENERAL ARMISTEAD AVENUE
CITY: AUDUBON
STATE: PA
ZIP: 19403
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0508
4/A
2023-09-01
2023-09-06
0
0001237831
GLOBUS MEDICAL INC
GMED
0001403373
DeFord John A
2560 GENERAL ARMISTEAD AVE
AUDUBON
PA
19403
1
0
0
0
0
Class A Common Stock
2023-09-01
4
A
0
15578
A
15578
D
Stock Option (Right to Buy Class A Common Stock)
54.23
2023-09-01
4
A
0
15000
0.00
A
2033-09-01
Class A Common Stock
15000
15000
D
Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, NuVasive, Inc. ("NuVasive") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into NuVasive (the "Merger"), with NuVasive continuing as a wholly owned subsidiary of the Issuer. At the effective time of the Merger, each NuVasive restricted stock unit award was accelerated, cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Issuer, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of NuVasive common stock underlying such award.
These options were granted on September 1, 2023, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on September 1, 2024, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
The original Form 4, filed on September 6, 2023, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported an expiration date of September 1, 2024, when in fact such expiration date is September 1, 2033.
/s/ Kelly G. Huller, Attorney-in-Fact
2023-09-06